Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending August 2015. The report serves as a notification of transactions involving directors, persons discharging managerial responsibilities (PDMRs), or connected persons, in accordance with DTR 3.1.4 R(1)(a) and (c).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of specific share transactions rather than a financial performance report.
Material Changes
The filing details an increase in the notional allocation of GSK American Depositary Shares (ADSs) on August 13, 2015. This change resulted from the revaluation of the cash element of the notional investment held within the GSK 401K plan. The transaction occurred at a price of $43.89 per ADS.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the disclosure of the specific director and connected person transactions noted above.
Key Facts for Investor Verification
- Transaction Date: August 13, 2015 (Notified August 14, 2015).
- Transaction Price: $43.89 per ADS.
- Director Involved: Dr. M. Slaoui received an increase of 20 ADSs.
- Connected Person Involved: Dr. K. Slaoui (connected to Dr. M. Slaoui) received an increase of 1 ADS.
- Cause: Revaluation of the cash element within the GSK 401K plan.